Clinical Trials Browser

Neoplasm, Residual × Azacitidine × Clear all

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Phase 1/2 Terminated

24 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06668558 2025-09-19

VERDI

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05904106 2024-12-02

VINCENT

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06066905 2023-10-27

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Phase 2 Completed

Myelodysplastic Syndromes, Neoplasm, Residual

NCT04748848 2023-03-02

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT03699384 2019-02-20

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual